Study of Atrasentan in Men With Non-Metastatic, Hormone-Refractory Prostate Cancer
A Phase III, Randomized Study of Atrasentan in Men With Non-Metastatic, Hormone-Refractory Prostate Cancer
Sponsor: Abbott
A PHASE3 clinical study on Prostatic Neoplasms, this trial is completed. The trial is conducted by Abbott and has accumulated 6 data snapshots since 2001. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Change History
6 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE3
▶ Show 1 earlier version
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE3
First recorded
Jun 2001
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Abbott
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
A Coruña, Spain, Albany, United States, Albuquerque, United States, Alcira (Valencia), Spain, Allentown, United States, Amsterdam, Netherlands, Anchorage, United States, Antwerp, Belgium, Arnhem, Netherlands, Athens, Greece and 187 more location s